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Fusion of single-nucleated myoblasts is essential for the formation of multinucleated
myocytes. Mechanisms that regulate myoblast fusion have been a focus of recent
studies.1–4 Transmembrane protein 8 (TMEM8C), also known as myomaker, is a highly
conserved muscle-specific transmembrane protein encoded by the MYMK gene. The
protein is expressed during early muscle development. Mymk-null mice die soon after
birth because of skeletal muscle deficiency. In these mice, skeletal muscle tissue is present
but consists of a smaller number of mononucleated cells indicating failure of myoblast
cell fusion.1 Myomaker is also expressed during muscle regeneration when it coordinates
fusion of satellite cells with residual muscle fibers to regenerate the damaged
muscle tissue. In the absence of myomaker, adult mouse muscle tissue is unable to
regenerate.5
In humans, mutations in the MYMK gene have recently been described in 8 individuals (aged
7–37 years) from 3 families with Carey-Fineman-Ziter syndrome (CFZS), a syndrome
encompassing a congenital myopathy with marked facial weakness and Pierre Robin sequence,
among other consistent features.6
Here, we report an additional and the oldest known patient-bearing mutations in the MYMK
gene, identified through whole-exome sequencing (WES). We provide insights into disease
progression, as well as ascertain features associated with the disorder.
Clinical description
The patient is a 69-year-old British white man with juvenile-onset proximal myopathy.
Distal muscles were also affected, although to a lesser extent. Weakness is mild and sym-
metrical with muscle power in the range of 3–4/5 for proximal muscles and 4–5/5 in distal
ones. The patient also had marked facial weakness, lagophthalmos, minimal limitations in
horizontal gaze, dysphagia, and chronic gastrointestinal (GI) symptoms. He reports al-
ternating diarrhea and constipation that have been attributed to irritable bowel syndrome.
The patient recalls weakness from his late teens when he was not as able as his peers. He
particularly recalls being unable to climb ropes or blow balloons. His symptoms were first
brought to medical attention at the age of 19 years when he dislocated his right knee and
was noted to have muscle weakness. Progression of the myopathy has not been remarkable,
and he remains ambulant, with the main complaint being the GI symptoms that are as-
sociated with food avoidance and weight loss.
He had no cardiac or respiratory involvement, and his cognition was intact. The patient had
mild dysmorphic features in the form of micrognathia, high-arched palate, and a prominent
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broad nasal tip (figure 1A). He also had spinal rigidity, sco-
liosis, bilateral pectoralis hypoplasia, and cryptorchidism. He
also developed epilepsy, sensorineural hearing loss, unilateral
cataracts, and glaucoma.
Serum creatinine kinase levels were mildly elevated
(500–1,000 IU/L), and EMG showed a picture suggestive of
a chronic mildly active necrotizing myopathy. MRI of his
lower limbs showed selective and asymmetric involvement
(figure 1B). Muscle biopsy showed nonspecific myopathic
features, namely, fiber-size variation and occasional central
nuclei (figure 2, A-F).
Genetic study
WES was performed at the Broad Institute of Harvard and
MIT’s Genomics Platform (Cambridge, MA) using >250
ng DNA (>2 ng/μL) in a 38-Mb targeted Illumina exome
capture. Data were then analyzed on the Seqr interface
(seqr.broadinstitute.org), initially using a candidate gene
approach, consisting of a panel of 416 genes (musclege-
netable.fr/, July 2016) known to be implicated in neuro-
muscular disorders, then searching for variants across the
whole exome. This identified 2 heterozygous variants in
the MYMK gene: c.271C>A (p.Pro91Thr) and c.553T>C
(p.Cys185Arg). Both variants were previously reported as
disease-causing mutations.6
Discussion
Our patient presented with a mild slow progressing my-
opathy. Extraskeletal muscle manifestations pointed to-
ward a syndromic myopathy rather than an isolated muscle
disease. At the age of 69 years, he remains ambulant and
shows slow progression of weakness. He shows no cardiac
or respiratory involvement. The patient has a mild form of
CFZS associated with MYMK mutations. Mainly proximal
myopathy places MYMK-associated CFZS in the differen-
tial diagnosis for the limb-girdle muscular dystrophies.
Pierre Robin sequence and cryptorchidism (in males) are
consistent features described in association with MYMK
mutations, and both may be a consequence of muscle
dysfunction in early development. A recent report associ-
ated CFZS with mutations in the STAC3 gene; a t-tubule
protein involved in excitation-contraction coupling. Dis-
tinguishing features of STAC3-CFZS are short stature and
malignant hyperthermia.7 Whether other clinical features
present in our patient are a consequence of MYMK
Figure 1 Clinical features and muscle MRI in MYMK-related Carey-Fineman-Ziter syndrome
(A.a and A.b) Front and profile facial photographs demonstrating lagophthalmos (A.a, patient attempting lid closure), muscle hypoplasia, retrognathia, and
broad nasal tip. (A.c and A.d) Wasting of intrinsic hand muscles and contracture deformities of the right little finger and the toes. (A.e, A.f) Scoliosis (A.e) and
generalizedmuscle atrophy with pectoralis muscle hypoplasia (A.f). (B) T2-weighted MRIs of the thighs (B.a) showing severe fatty replacement of hamstrings,
thigh adductors, and sartorius muscles, with relative sparing of the gracilis and quadriceps muscles bilaterally, and of the calves (B.b) showing asymmetric
involvement withmoremarked fatty replacement inmuscle of the right leg. Gastrocnemius and soleusmuscles are severely affected, and the tibialis anterior
on the right is relatively spared.
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mutations remains to be established through continued
follow-up of the known patients6 and diagnosis and follow-
up of new patients with CFZS.
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